Temazepam
Viewing r1 — May 9, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Temazepam is a synthetic depressant of the benzodiazepine class. It is the 3-hydroxy derivative of diazepam, distinguished by simpler metabolism and fewer active metabolites.[1] Temazepam is a non-selective positive allosteric modulator of GABA-A receptors, producing its effects by amplifying the brain's primary inhibitory signaling system.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
benzodiazepines, barbiturates, zolpidem +3 morebenzodiazepines, barbiturates, zolpidem, zopiclone, zaleplon, alcohol show less
Synthesized in 1964 at Hoffmann-La Roche, temazepam received FDA approval in 1981 and is prescribed primarily for short-term insomnia. Its gel capsule formulation drove a major injection misuse crisis in the United Kingdom and Australia — injected gel solidified in blood vessels, causing gangrene and amputation.[3][4] Capsule formulations were permanently withdrawn; temazepam remains available only as tablets, classified as Schedule IV internationally.
Subjective effects include sedation, anxiolysis, muscle relaxation, and anterograde amnesia. The experience is one of gradual, enveloping heaviness — a warm cognitive dimming and physical loosening that builds steadily toward sleep, with a broader bodily weight than the targeted sedation of newer sleep medications. Morning-after grogginess, memory gaps for events during peak effect, and psychomotor impairment are characteristic unsought effects.
Temazepam produces physical dependence with regular use, and while rarely fatal alone, its lethality increases substantially when combined with opioids or alcohol.[5] Tolerance to the sleep-promoting effect develops within two to three weeks of nightly use,[6] driving dose escalation that deepens dependence without restoring efficacy.[7] Decades of clinical use provide a well-characterized safety profile, though substance-specific lethal dose values and receptor binding affinities remain unpublished.
History[edit]
Discovery
Temazepam was synthesized in 1964 at Hoffmann-La Roche, the laboratory that produced chlordiazepoxide, diazepam, and nitrazepam. Structurally, it is the 3-hydroxy, N1-methyl derivative of diazepam — a deliberate modification that routes metabolism through a simpler conjugation pathway rather than the oxidative processing required by its parent compound.[1] The first human pharmacokinetic studies, published in 1977, characterized plasma profiles following oral administration of soft gelatin capsules and confirmed that the soft gel formulation produced significantly faster absorption than hard capsules.[8][9]
Clinical adoption and the gel capsule crisis
Temazepam was marketed in the United Kingdom as Normison and Euhypnos, and received FDA approval in 1981 as Restoril in the United States. By the mid-1980s, its gel capsules had become widely injected in Scotland — users heated the capsules to liquefy the contents for intravenous use. The consequences were catastrophic: temazepam is nearly insoluble in water, and injected gel solidified at body temperature, causing vascular blockage, gangrene, and amputation.[3][4][10] Glasgow and Edinburgh saw sharp increases in drug-related deaths during 1990–1992, with temazepam — frequently combined with heroin — identified as a major contributor.[11]
Modern era
The UK withdrew gel capsules in 1996; Australia followed in 2004.[3] Temazepam remains available only as tablets, positioned by clinical guidelines as second-line pharmacotherapy for insomnia after cognitive behavioral therapy.[12][13] Recent clinical investigation includes a Phase III trial evaluating temazepam for insomnia in advanced cancer patients.[14]
The gel capsules earned street names reflecting their appearance: "Jellies," "Rugby Balls," and "Eggs" in the United Kingdom. The injection crisis gave temazepam a uniquely notorious reputation among benzodiazepines — one defined not by recreational appeal but by the severity of vascular injuries that followed misuse of a specific formulation.
Chemistry[edit]
Structural class
Temazepam belongs to the 1,4-benzodiazepine family, classified specifically as a 3-hydroxybenzodiazepinone. The 3-hydroxy group at C-3 and the N1-methyl substituent distinguish it from its parent compound diazepam, of which it is a direct metabolite. The 7-chloro and 5-phenyl substituents are conserved features shared with diazepam, oxazepam, and several other clinical benzodiazepines.
Temazepam's structural relationship to oxazepam is particularly close: oxazepam is temazepam's own N-desmethyl metabolite, produced by minor oxidative demethylation.[15]
Molecular identity
| Molecular formula | C₁₆H₁₃ClN₂O₂ |
| Molecular weight | 300.74 g/mol |
The core structure consists of a 1,4-benzodiazepine ring fused to a chloro-substituted benzene ring at position 7, with a phenyl group at position 5, a methyl on the N1 nitrogen, a carbonyl at C-2, and a hydroxyl at C-3.
Stereochemistry
The hydroxyl group at C-3 creates a chirality center, and pharmaceutical preparations contain both (R)- and (S)-enantiomers as a racemic mixture. Whether one enantiomer preferentially contributes to the hypnotic, anxiolytic, or amnestic effects has not been determined.citation needed
Physical properties
Temazepam is a white to slightly yellow crystalline powder, freely soluble in chloroform but very slightly soluble in water. This near-insolubility in water is directly relevant to its injury profile: when gel capsule contents were injected intravenous, the compound solidified at body temperature, causing mechanical vascular blockage on top of direct chemical damage to blood vessel walls.[3][16]
Pharmacology[edit]
Mechanism of action
Temazepam binds at the benzodiazepine site on GABA-A receptors — the brain's primary inhibitory receptor — and amplifies the effect of the neurotransmitter GABA. When GABA binds the receptor, temazepam increases the flow of chloride ions into the neuron, making it harder to fire. The resulting widespread reduction in neural activity produces sedation, anxiety relief, muscle relaxation, memory suppression, and anticonvulsant effects.[2]
Unlike newer sleep medications such as zolpidem and zaleplon, which target a specific receptor subtype, temazepam acts broadly across multiple GABA-A receptor variants. This non-selective binding accounts for its combined hypnotic, anxiolytic, muscle-relaxant, and amnestic properties — a broader pharmacological profile than the Z-drug class.[17]
No substance-specific binding affinity values have been published for temazepam; its pharmacological characterization relies on class-level properties of non-selective benzodiazepines.citation needed
Pharmacokinetics
Temazepam is well absorbed orally with high bioavailability, as very little is lost to first-pass liver processing (approximately 8%).[2] Peak blood levels are reached within 1–2 hours with current tablet formulations. The half-life ranges from 3.5 to 18.4 hours (mean 8.8 hours), and the compound is approximately 96% bound to plasma proteins.[2]
The key metabolic distinction of temazepam is its primary elimination through direct glucuronide conjugation — a Phase II pathway — rather than the CYP450-dependent oxidation used by most benzodiazepines.[15][2] The resulting glucuronide metabolite is inactive and excreted by the kidneys (80–90% of the dose). A minor pathway produces oxazepam, itself an active benzodiazepine.[15]
This conjugation-first metabolism means temazepam largely avoids the drug-drug interactions that complicate therapy with CYP-dependent benzodiazepines like diazepam, alprazolam, and triazolam.[1] In elderly patients, conjugative metabolism remains relatively stable, but increased brain sensitivity to the drug produces stronger sedation at any given blood level.[1]
Neuroscience[edit]
Where it acts
Temazepam's effects arise from amplifying inhibitory GABA signaling across multiple brain regions simultaneously. In the thalamus and cortex, potentiation of GABA-A receptors containing α1 subunits suppresses arousal signals and facilitates sleep onset.[2] In the amygdala and limbic structures, α2-containing receptors mediate anxiety reduction.[18][19]
In the hippocampus, α5-containing receptors disrupt memory encoding, producing the dose-dependent anterograde amnesia that defines much of the temazepam experience.[18] Spinal cord and brainstem receptors containing α2 and α3 subunits reduce motor neuron excitability, accounting for the muscle-relaxant effect.
Tolerance and reward
Repeated use triggers adaptive changes at GABA-A receptors — receptor internalization, altered subunit expression, and uncoupling of the allosteric mechanism — producing the hypnotic tolerance documented within 2–3 weeks of nightly use.[6] The mesolimbic pathway involves indirect disinhibition of dopamine neurons: temazepam potentiates GABA-A receptors on inhibitory interneurons in the ventral tegmental area, releasing dopamine neurons from their normal braking, and driving the reinforcement that underlies compulsive use.citation needed
Whether the (R)- or (S)-enantiomer preferentially drives hypnotic, anxiolytic, or amnestic effects remains unknown. The divergence between laboratory-demonstrated tolerance within weeks[6] and some clinical populations maintaining efficacy over months[20] is unexplained — genetic variation in receptor subunit expression and prior benzodiazepine exposure are candidate factors. Whether temazepam's effects on deep sleep and REM sleep differ meaningfully from other non-selective benzodiazepines has not been characterized by sleep-stage recording.citation needed
Subjective Effects[edit]
The temazepam experience is defined by a gradual, enveloping sedation that spreads from anxiolysis into full-body heaviness and cognitive dimming. At lower doses, the effect is primarily one of tension relief — mental chatter quiets, muscles loosen, and the transition toward sleep feels natural rather than forced. At higher doses, the sedation deepens into pronounced mental fog, motor coordination deteriorates, and anterograde amnesia becomes a dominant feature: events during peak effect may be partially or entirely absent from later recall.
Compared to diazepam, temazepam offers similar anxiety relief with more predictable clearance and less next-day carryover from active metabolites. Against zolpidem, temazepam's non-selective receptor profile produces more pronounced muscle relaxation and a heavier subjective weight, with greater amnestic burden at equivalent sleep-promoting doses.
Effect Grid
The standard clinical dose range, producing progressive sedation, clear anxiety suppression, and definite muscle relaxation. Thought deceleration is prominent — cognitive processing slows noticeably. Anterograde amnesia becomes dose-dependent and clinically significant: events occurring during peak effect may be incompletely recalled or entirely absent from later memory. Emotional suppression deepens, and disinhibition may emerge.
Physically, bodily heaviness is pronounced and motor control impairment is measurable. Sleep induction becomes the dominant effect at the upper end of this range. Morning-after psychomotor impairment and memory fog are documented, particularly above 15 mg and in elderly patients.
The 15 mg and 20 mg doses are the most commonly studied in clinical trials. At 30 mg (upper bound), cognitive euphoria may be noted alongside significant functional impairment. Delusions of sobriety — the subjective belief of normal functioning while objectively impaired — become relevant at this level.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Vestibular distortion · Visual processing suppression
Physical fatigue · Dizziness · Body high · Breathing alteration · Tactile euphoria · Dry mouth · Nystagmus (eye wobbles) · Headache · Laughter fits · Nausea · Pain suppression · Abnormal heartbeat
Breathing alteration · Tactile euphoria · Dry mouth · Nystagmus (eye wobbles) · Headache · Laughter fits · Nausea · Pain suppression
Thought deceleration · Language suppression · Memory suppression · Cognitive fatigue · Information processing suppression · Motivation suppression · Memory fragmentation · Cognitive euphoria · Confusion · Suggestibility enhancement · Thought disorganization · Compulsive redosing urge · Humor enhancement · Amnesia · Delirium
Cognitive fatigue · Information processing suppression · Motivation suppression · Memory fragmentation · Cognitive euphoria · Confusion · Thought disorganization · Compulsive redosing urge · Humor enhancement · Amnesia · Delirium
Emotional lability · Dysphoria · Irritability
Automaticity · Craving · Depersonalization · Derealization · Cognitive disconnection
Cognitive disconnection
Timeline
Gradual relaxation emerges with initial anxiety suppression and mild sedation. A subtle bodily heaviness develops as muscle tension begins to dissolve.
Full sedation, pronounced anxiety suppression, and clear muscle relaxation. Cognitive slowing is prominent — thought deceleration and analysis suppression are noticeable. Memory encoding is impaired; anterograde amnesia is dose-dependent.
Sustained sedation with sleep maintenance as the dominant effect. Motor control impairment persists. Emotional suppression and bodily heaviness continue at a steady level.
Gradual lightening of sedation. Sleep becomes lighter, residual relaxation and mild cognitive fog persist. Motor impairment diminishes but remains measurable.
Morning-after residual effects — psychomotor impairment, memory fog, and possible daytime drowsiness. Intensity is dose-dependent; documented clinically at doses of 15 mg and above.
⚠ Do not drive or operate heavy machinery for at least 8 hours after taking temazepam.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- Severe
- Tolerance buildup
- moderate
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- benzodiazepines · barbiturates · zolpidem
Toxicity
Acute toxicity
Temazepam overdose presents with excessive sedation, confusion, impaired coordination, diminished reflexes, slowed breathing, and in severe cases, coma.[2] Temazepam alone is rarely fatal; nearly all temazepam-related deaths involve co-ingestion with other depressants — particularly opioids and alcohol — which produce combined respiratory depression exceeding what either substance causes alone.[5]
StatPearls states that temazepam is "approximately 10 times more hazardous than diazepam" in overdose.[2] This claim could not be traced to a primary published source.safety citation needed No published lethal dose data exist for temazepam in humans or animals.safety citation needed
Injection toxicity
Respiratory effects
In patients with severe stable COPD, temazepam 10 mg did not significantly impair breathing or gas exchange.[21] However, benzodiazepines are contraindicated in obstructive sleep apnea because muscle relaxation can worsen airway collapse. Respiratory depression remains the primary mechanism of death in polydrug overdose.
Pregnancy
Elderly
Falls are the primary safety concern in older adults taking temazepam. Hypnotic medications impair balance and standing steadiness.[22] Temazepam and triazolam carry similar hip fracture risk.[23] A meta-analysis of 24 trials found harmful cognitive effects 4.78 times more common with sedative-hypnotics than placebo in older adults (95% CI 1.47–15.47).[24]
Overdose management
Flumazenil can reverse benzodiazepine effects but is not recommended for routine overdose management. A meta-analysis found significantly more adverse events with flumazenil than placebo, including dangerous heart rhythm changes and seizures.[25] Standard overdose management is supportive care: maintaining the airway and monitoring vital signs.
Psychological risks
Temazepam produces dose-dependent anterograde amnesia — impaired ability to form new memories during the period of drug activity.[18] At therapeutic doses, this appears as difficulty recalling events after ingestion; at higher doses, complete memory gaps may occur.
Disinhibition is a recognized benzodiazepine class effect. Post-marketing reports include rare paradoxical reactions — agitation, aggression, and paranoia — more common in elderly patients and those with pre-existing psychiatric conditions.[2]
Delusions of sobriety — the belief that one is functioning normally while objectively impaired — may drive dose escalation and risky behavior during intoxication.
Rebound insomnia affects 26–58% of users following discontinuation of temazepam 20 mg,[26] often accompanied by mood disturbance.[6] Vivid dreams and nightmares are reported as adverse effects during use.[2]
Tolerance & dependence
Tolerance to temazepam's sleep-promoting effect develops with continued use. Controlled sleep laboratory studies demonstrated significant tolerance within 14–22 nights of nightly dosing.[6] Contrasting findings from a 3-month clinical trial (n = 175) showed temazepam 30 mg maintaining efficacy without tolerance,[20] suggesting tolerance development may depend on individual factors and measurement context.
Cross-tolerance exists with all benzodiazepines and other GABA-A modulators.[27]
Physical dependence develops with regular use and produces a withdrawal syndrome on cessation. Symptoms include rebound effect insomnia, anxiety, agitation, tremor, sensory disturbances, and autonomic instability; rarely, seizures and delirium occur.[7][27]
- Onset: 1–3 days after last dose
- Duration: Typically weeks; some patients experience protracted withdrawal lasting months
- Management: Gradual dose reduction is preferred over abrupt cessation. Melatonin has been studied as an aid to benzodiazepine withdrawal in older patients[28]
Drug interactions
Temazepam's interaction profile is dominated by pharmacodynamic effects — additive depression with other sedating substances — rather than metabolic drug-drug interactions. Because temazepam bypasses the CYP450 enzyme system,[2][1] the extensive metabolic interactions seen with alprazolam, triazolam, and midazolam do not apply.
Opioid co-administration produces additive respiratory depression and is a leading cause of drug-related death. The FDA has issued a boxed warning against concurrent benzodiazepine-opioid prescribing.[2][5]
Alcohol co-use produces combined depressant effects with potentially fatal respiratory failure.[5] Other benzodiazepines, barbiturates, sedating antihistamines, antipsychotics, and phenothiazines carry additive depressant risk.[2]
MAO inhibitors are listed as moderate interactants, though the precise interaction mechanism is not fully characterized.[2]
Contraindications
Absolute contraindications:
- Pregnancy (FDA Category X): Documented birth defects in animal models and neonatal withdrawal in humans[2]
- Known hypersensitivity to temazepam or other benzodiazepines[2]
- Acute narrow-angle glaucomacitation needed
Relative contraindications:
- Obstructive sleep apnea: Muscle relaxation may worsen airway collapse
- Severe liver disease: Although temazepam's primary metabolism avoids CYP enzymes, severe liver impairment may affect all metabolic pathways
- Myasthenia gravis: Muscle-relaxant effects may worsen neuromuscular weakness[2]
- Acute alcohol intoxication: Additive depressant risk[2]
- Severe depression with suicidal thoughts: Depressant effects and disinhibition may increase suicide risk[2]
- History of substance use disorder: Elevated misuse and dependence risk[7]
- Elderly patients: Increased sensitivity and fall risk warrant particular caution[1][24]
Harm Reduction[edit]
Forms & Identification
Pharmaceutical temazepam tablets are manufactured with consistent dosing and identifiable by imprint codes. The primary identification concern is not adulteration of genuine pharmacy stock but verifying that tablets obtained outside a pharmacy are genuinely temazepam rather than counterfeit products containing more potent benzodiazepines or other active compounds. Reagent testing does not reliably distinguish between different benzodiazepines; pill identification databases matching imprint codes provide the most practical verification for pharmaceutical tablets.
Guidelines
- Take only the prescribed dose. Higher doses intensify amnesia and psychomotor impairment without proportionally improving sleep quality.
- Take temazepam immediately before getting into bed. Walking around, socializing, or using the phone after dosing increases the likelihood of amnestic behavior and impaired decisions.
- Allow a full 7–8 hours for sleep. Taking temazepam without sufficient time for sleep increases morning-after impairment.
- Do not drive or operate machinery the morning after use until certain that alertness has fully returned.
- Do not use nightly for more than 2–3 weeks without medical review. Tolerance to the sleep-promoting effect develops within this window, and physical dependence begins.
- Never crush, dissolve, or inject tablets. Injection of temazepam in any form causes severe vascular injury.
Set & Setting
Temazepam is a sedative-hypnotic taken primarily at bedtime. The environment should support safe sleep: a secure location where the user will not need to drive, operate machinery, or make important decisions. Because temazepam produces anterograde amnesia, anything requiring memory formation — conversations, commitments, financial decisions — should be completed before dosing.
The amnestic and disinhibiting effects make temazepam particularly risky in social or unfamiliar settings where impaired judgment may go unnoticed. The subjective sense of normal functioning while objectively impaired (delusions of sobriety) is a recognized class effect that increases risk-taking during intoxication.
Aftercare & integration. Temazepam is a sedative-hypnotic, and post-use care focuses on managing residual impairment and addressing the underlying sleep problem. Morning-after grogginess, slowed reaction time, and subtle memory suppression can persist for several hours after waking — plan accordingly for driving, work, and decision-making.
If temazepam has been used nightly for more than a few weeks, discontinuation should be gradual and ideally supervised. Rebound insomnia is common and temporary but can feel severe enough to drive immediate reinstatement of use. Non-pharmacological sleep strategies — consistent sleep schedule, reduced evening stimulation, cognitive behavioral therapy for insomnia — are the foundation of long-term sleep improvement.
Recovery & Support
Benzodiazepine dependence is a well-recognized medical condition with established treatment pathways. Gradual dose tapering — reducing the dose in small steps over weeks to months — is the standard approach and is far safer than abrupt cessation, which risks seizures and severe rebound symptoms.
Medical supervision during taper is strongly recommended. Some patients benefit from switching to a longer-acting benzodiazepine (such as diazepam) to smooth the reduction curve. Melatonin has been studied as a supportive aid during benzodiazepine withdrawal in older adults.[28]
Support resources include the SAMHSA National Helpline (1-800-662-4357), the Benzodiazepine Information Coalition, and peer support communities. Dependence on a prescribed medication is not a moral failing — it is a predictable physiological adaptation that responds to structured treatment.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Breathing becomes very slow, shallow, or stops
- Lips or fingertips turn blue or gray
- The person cannot be woken by loud voice or sternal rub
- Seizures occur
- Severe confusion or agitation beyond normal sedation
Immediate steps:
- 1. Call emergency services immediately if breathing is compromised, the person is unresponsive, or seizures occur.
- 2. Place the person in the recovery position (on their side) to protect the airway.
- 3. Do not induce vomiting.
- 4. Stay with the person and monitor breathing until help arrives.
- 5. If opioids may also have been taken and naloxone is available, administer it — naloxone reverses opioid but not benzodiazepine effects.
What to tell the dispatcher: Name the substance (temazepam / benzodiazepine), estimated amount taken, time of ingestion, any other substances involved, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Reversal agent: Flumazenil can reverse benzodiazepine effects but carries risks of seizure and dangerous heart rhythm changes. It is administered only in hospital settings — do not delay calling emergency services in anticipation of reversal.
Legal Status[edit]
Temazepam is internationally controlled as a Schedule IV substance under the United Nations Convention on Psychotropic Substances. Most jurisdictions classify it as a prescription-only controlled substance. The United Kingdom applies notably stricter controls than for most benzodiazepines, a regulatory response driven by the injection misuse crisis of the 1980s and 1990s.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule IV (Controlled Substances Act) | Prescription required; maximum 5 refills within 6 months[29] |
| United Kingdom | Class C, Schedule 3 (Misuse of Drugs Act 1971 / MDR 2001) | Safe custody required; stricter than Schedule 4 classification applied to most benzodiazepines[30] |
| Australia | Schedule 4 (Prescription Only) | Capsule formulations permanently withdrawn March 2004; tablet-only availability[3] |
| Canada | Schedule IV (CDSA) | Prescription required[30] |
| International | Schedule IV (UN Convention on Psychotropic Substances) | International treaty obligation for signatory states[30] |
The United Kingdom's classification of temazepam as Class C / Schedule 3 — rather than the Schedule 4 designation applied to most benzodiazepines — imposes additional safe custody requirements and reflects the documented public health impact of temazepam injection misuse during the 1990s.[30]
references
- [1]
- [2]
- [3]
- [4] ^abcDodd TJ, Scott RN, Woodburn KR, Going JJ (1994) Limb ischaemia after intra-arterial injection of Temazepam gel: histology of nine cases — Journal of clinical pathology PMID:8063932
- [5] ^abcdGudin JA, Mogali S, Jones JD, Comer SD (2013) Risks, management, and monitoring of combination opioid, benzodiazepines, and/or alcohol use — Postgraduate medicine doi:10.3810/pgm.2013.07.2684
- [6]